Related MeSH Hierarchy (7)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urogenital Neoplasms » Genital Neoplasms, Female » Ovarian Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Genital Diseases, Female » Adnexal Diseases » Ovarian Diseases » Ovarian Neoplasms
Diseases [C] » Urogenital Diseases [C12] » Urogenital Neoplasms » Genital Neoplasms, Female » Ovarian Neoplasms
Diseases [C] » Neoplasms [C04] » Neoplasms by Site » Endocrine Gland Neoplasms » Ovarian Neoplasms
Diseases [C] » Endocrine System Diseases [C19] » Endocrine Gland Neoplasms » Ovarian Neoplasms
Diseases [C] » Endocrine System Diseases [C19] » Gonadal Disorders » Ovarian Diseases » Ovarian Neoplasms
Description
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. MeSH
Hierarchy View
Subtype Terms (9)
Brenner Tumor
22 drugs (16 approved, 6 experimental)
Carcinoma, Endometrioid
15 drugs (9 approved, 6 experimental)
Carcinoma, Ovarian Epithelial
150 drugs (61 approved, 89 experimental)
Hereditary Breast and Ovarian Cancer Syndrome
10 drugs (6 approved, 4 experimental)
Approved Indicated Drugs (19)
Phase 4 Indicated Drugs (20)
Phase 2 Indicated Drugs (339)
allogeneic hematopoietic stem cells (Hemacord)
allogeneic natural killer cells
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
autologous dendritic cells loaded with autologous tumor lysate
dendritic cell tumor fusion vaccine
herpes simplex thymidine kinase
hyaluronidase (human recombinant) (Hylenex)
hydroxychloroquine (plaquenil)
modified vaccinia ankara-5t4 vaccine
modified vaccinia virus ankara vaccine expressing p53
n-(4-hydroxyphenyl)all-trans retinamide
oncolytic measles virus encoding thyroidal sodium iodide symporter
peg-pei-cholesterol lipopolymer-encased il-12 dna plasmid vector gen-1
recombinant adenoviral human p53 gene
Phase 1 Indicated Drugs (285)
anti-ny eso-1 tcr-transduced t cells
autologous genetically modified mage a4c1032 t cells
autologous ny-eso-1-specific cd8-positive t lymphocytes
ex vivo cd3/cd28-costimulated vaccine-primed peripheral blood autologous t cells
ex vivo-expanded her2-specific t cells
follicle stimulating hormone receptor t cells
genetically engineered ny-eso-1-specific t lymphocytes
globo-h-gm2-stn-tf-tn-klh conjugate
her2bi-armed activated t cells
in111 monoclonal antibody hu3s193
mfe23 scfv-expressing autologous anti-cea mfez t lymphocytes
mov-gamma chimeric receptor gene
multi-epitope folate receptor alpha peptide vaccine
mvf-her-2(628-647)-crl 1005 vaccine
ovarian cancer peptide vaccine
Other Experimental Indicated Drugs (29)
Organization Involved with Phase 4 Indications (15)
Organization Involved with Phase 3 Indications (152)
Arbeitsgemeinschaft Gynaekologische Onkologie Austria
Australia New Zealand Gynaecological Oncology Group
BioNumerik Pharmaceuticals, Inc.
Boryung Pharmaceutical Company
British Columbia Cancer Agency
Cancer and Leukemia Group B (CALGB)
Charité University, Berlin, Germany
Chinese Academy of Medical Sciences
Clinica Universidad de Navarra
Cooperative Ovarian Cancer Group for Immunotherapy Network
Eastern Cooperative Oncology Group
EBMT Solid Tumors Working Party
European Network for Gynaecological Oncological Trial
European Network for Gynaecological Oncological Trial Groups
European Organisation for Research and Treatment of Cancer
Franklin Square Hospital Center
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
Grupo Español de Investigación en Cáncer de Ovario
Gynecological Oncology Center South (GOCZ)
Gynecologic Oncology Trial & Investigation Consortium
Hospital general Universitario de Ciudad Real
Huazhong University of Science and Technology
Institut de Cancérologie de Lorraine
Japanese Gynecologic Oncology Group
Multicenter Italian Trials in Ovarian Cancer
National Cancer Institute (NCI)
National Health and Medical Research Council, Australia
Nordic Society for Gynaecologic Oncology
North Eastern Germany Society of Gynaecologic Oncology
OncoQuest Pharmaceuticals Inc.
People's Liberation Army of China
Organization Involved with Phase 2 Indications (372)
American Society of Clinical Oncology
Asian Gynecologic Oncology Group
Cancer Treatment Research Foundation
Catholic University of Sacred Heart, Rome
Centre Georges Francois Leclerc
Chao Family Comprehensive Cancer Center
City of Hope National Medical Center
Department of Radiation Oncology
East and North Hertfordshire NHS Trust
ECOG-ACRIN Cancer Research Group
European Interbalkan Medical Center
French Cancer Research Hospital Program
GCIG: Gynecologic Cancer InterGroup
Georgia Institute of Technology
Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH
Groupe Hospitalier Diaconesses Croix Saint Simon
Grupo Español de Tumores Huérfanos e Infrecuentes
Gynecologic Oncology Associates
Gynecologic Oncology Trial and Investigation Consortium, Japan
Hellenic Cooperative Oncology Group
Hellenic Oncology Research Group
Henry M. Jackson Foundation for the Advancement of Military Medicine
Herbert Irving Comprehensive Cancer Center
Hoosier Cancer Research Network
Hospital HM Universitario Sanchinarro
Hospital Universitario Fundación Alcorcón
Hospital Universitario Madrid Sanchinarro
Hospital Universitari Son Dureta
Icahn School of Medicine at Mount Sinai
Instituto de Investigação em Imunologia
Instituto de Medicina Integral Professor Fernando Figueira
Instituto Europeo de Oncologia
James Graham Brown Cancer Center
Jiangsu Cancer Institute & Hospital
Jilin Provincial Tumor Hospital
KK Women's and Children's Hospital
Korea Institute of Radiological & Medical Sciences (KIRAMS)
Krankenhaus der Barmherzigen Schwestern Linz
Latin American Cooperative Oncology Group
Ligue contre le cancer, France
Medical University of South Carolina
Memorial Health University Medical Center
Memorial Sloan-Kettering Cancer Center
Mid-Atlantic Gynecologic Oncology & Pelvic Surgical Associates
National Cancer Institute, France
National Cheng Kung University
National Comprehensive Cancer Network
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
National University of Singapore
New Mexico Cancer Care Alliance
New York Presbyterian Hospital
Ontario Institute for Cancer Research
Philipps University of Marburg
Prologue Research International
Royal Marsden Hospital NHS Trust
Russian Academy of Medical Sciences
Samyang Biopharmaceuticals Corporation
San Antonio Military Medical Center
Shanghai Gynecologic Oncology Group
Shenzhen Geno-Immune Medical Institute
Shenzhen Hank Bioengineering Institute
Southeastern Gynecologic Oncology
South Plains Oncology Consortium
State University of New York, Buffalo
St. Joseph's Hospital and Medical Center - Phoenix, Arizona
The Christie NHS Foundation Trust
The First People's Hospital of Changzhou
The University of Texas, Dallas
Translational Research in Oncology
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universitario de Santiago, Spain
Universitätsklinikum Mannheim, Frauenklinik
University of Alabama, Birmingham
University of British Columbia
University of California, Irvine
University of California, San Diego
University of California, San Francisco
University of Electronic Science and Technology of China
University of North Carolina at Chapel Hill
University of Southern California
University of Southern Denmark
University of Texas at Houston
University of Texas, San Antonio
University of Western Australia
Vita-Salute University of Milano. Italy
Organization Involved with Phase 1 Indications (79)
National Hospital Organisation Shikoku Cancer Centre
Oncology Institute of Southern Switzerland
Oregon Health and Science University
Ospedale S. Giovanni Bellinzona
Shanghai Zhangjiang Biotechnology Limited Company
Organization Involved with Other Experimental Indications (7)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
